142 related articles for article (PubMed ID: 38714747)
1. Prospective manipulation of the gut microbiome with microbial ecosystem therapeutic 4 (MET4) in HPV-related locoregionally-advanced oropharyngeal cancer squamous cell carcinoma (LA-OPSCC) undergoing primary chemoradiation: ROMA2 study.
Oliva M; Heirali A; Watson G; Rooney AM; Cochrane K; Jennings S; Taylor R; Xu M; Hosni A; Hope A; Bratman SV; Chepeha D; Weinreb I; Perez-Ordonez B; Nin RM; Waldron J; Xu W; Hansen AR; Siu LL; Coburn B; Spreafico A
Br J Cancer; 2024 Jun; 130(12):1936-1942. PubMed ID: 38714747
[TBL] [Abstract][Full Text] [Related]
2. Transitions in oral and gut microbiome of HPV+ oropharyngeal squamous cell carcinoma following definitive chemoradiotherapy (ROMA LA-OPSCC study).
Oliva M; Schneeberger PHH; Rey V; Cho M; Taylor R; Hansen AR; Taylor K; Hosni A; Bayley A; Hope AJ; Bratman SV; Ringash J; Singh S; Weinreb I; Perez-Ordoñez B; Chepeha D; Waldron J; Xu W; Guttman D; Siu LL; Coburn B; Spreafico A
Br J Cancer; 2021 Apr; 124(9):1543-1551. PubMed ID: 33750907
[TBL] [Abstract][Full Text] [Related]
3. Costs of Definitive Chemoradiation, Surgery, and Adjuvant Radiation Versus De-Escalated Adjuvant Radiation per MC1273 in HPV+ Cancer of the Oropharynx.
Waddle MR; Ma DJ; Visscher SL; Borah BJ; May JM; Price KA; Moore EJ; Patel SH; Hinni ML; Chintakuntlawar AV; Garcia JJ; Graner DE; Neben-Wittich MA; Garces YI; Hallemeier CL; Price DL; Kasperbauer JL; Janus JR; Foote RL; Miller RC
Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):396-402. PubMed ID: 33359567
[TBL] [Abstract][Full Text] [Related]
4. Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002).
Yom SS; Torres-Saavedra P; Caudell JJ; Waldron JN; Gillison ML; Xia P; Truong MT; Kong C; Jordan R; Subramaniam RM; Yao M; Chung CH; Geiger JL; Chan JW; O'Sullivan B; Blakaj DM; Mell LK; Thorstad WL; Jones CU; Banerjee RN; Lominska C; Le QT
J Clin Oncol; 2021 Mar; 39(9):956-965. PubMed ID: 33507809
[TBL] [Abstract][Full Text] [Related]
5. Impact of chemotherapy regimen on treatment outcomes in patients with HPV-associated oropharyngeal cancer with T4 disease treated with definitive concurrent chemoradiation.
Bhattasali O; Ryoo JJ; Thompson LDR; Abdalla IA; Chen J; Iganej S
Oral Oncol; 2019 Aug; 95():74-78. PubMed ID: 31345397
[TBL] [Abstract][Full Text] [Related]
6. Standard of care vs reduced-dose chemoradiation after induction chemotherapy in HPV+ oropharyngeal carcinoma patients: The Quarterback trial.
Misiukiewicz K; Gupta V; Miles BA; Bakst R; Genden E; Selkridge I; Surgeon JT; Rainey H; Camille N; Roy E; Zhang D; Ye F; Jia R; Moshier E; Bonomi M; Hwang M; Som P; Posner MR
Oral Oncol; 2019 Aug; 95():170-177. PubMed ID: 31345387
[TBL] [Abstract][Full Text] [Related]
7. Upfront Neck Dissection for Treatment Selection and Improvement in Quality of Life as a Novel Treatment Paradigm for Deintensification in HPV+ OPSCC.
Swiecicki PL; Bellile E; Dragovic AF; McHugh J; Udager A; Mierzwa ML; Shah J; Heft-Neal M; Rosko A; Malloy KM; Casper K; Chinn SB; Shuman AG; Stucken C; Chepeha DB; Wolf GT; Bradford CR; Eisbruch A; Prince ME; Worden FP; Spector ME
Clin Cancer Res; 2024 Jun; 30(11):2393-2401. PubMed ID: 38517480
[TBL] [Abstract][Full Text] [Related]
8. Primary surgery for human papillomavirus-associated oropharyngeal cancer: Survival outcomes with or without adjuvant treatment.
Cramer JD; Ferris RL; Kim S; Duvvuri U
Oral Oncol; 2018 Dec; 87():170-176. PubMed ID: 30527235
[TBL] [Abstract][Full Text] [Related]
9. Outcomes after primary intensity-modulated radiation therapy for oropharyngeal squamous cell carcinoma at a New Zealand regional cancer centre: Impact of p16 status.
Maqsood S; Jameson MB; De Groot C; Hartopeanu C; Yasin NABHM; Thotathil Z
Cancer Rep (Hoboken); 2018 Jun; 1(1):e1001. PubMed ID: 32729235
[TBL] [Abstract][Full Text] [Related]
10. Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy.
Oliva M; Huang SH; Xu W; Su J; Hansen AR; Bratman SV; Ringash J; Jang R; Cho J; Bayley A; Hope AJ; Chen E; Giuliani M; Waldron J; Weinreb I; Perez-Ordonez B; Chepeha D; Kim J; O Sullivan B; Siu LL; Spreafico A
Eur J Cancer; 2019 Sep; 118():112-120. PubMed ID: 31330486
[TBL] [Abstract][Full Text] [Related]
11. Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma.
Chera BS; Amdur RJ; Tepper JE; Tan X; Weiss J; Grilley-Olson JE; Hayes DN; Zanation A; Hackman TG; Patel S; Sheets N; Weissler MC; Mendenhall WM
Cancer; 2018 Jun; 124(11):2347-2354. PubMed ID: 29579339
[TBL] [Abstract][Full Text] [Related]
12. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.
Gillison ML; Trotti AM; Harris J; Eisbruch A; Harari PM; Adelstein DJ; Jordan RCK; Zhao W; Sturgis EM; Burtness B; Ridge JA; Ringash J; Galvin J; Yao M; Koyfman SA; Blakaj DM; Razaq MA; Colevas AD; Beitler JJ; Jones CU; Dunlap NE; Seaward SA; Spencer S; Galloway TJ; Phan J; Dignam JJ; Le QT
Lancet; 2019 Jan; 393(10166):40-50. PubMed ID: 30449625
[TBL] [Abstract][Full Text] [Related]
13. Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal Cancer.
Chera BS; Kumar S; Shen C; Amdur R; Dagan R; Green R; Goldman E; Weiss J; Grilley-Olson J; Patel S; Zanation A; Hackman T; Blumberg J; Patel S; Thorp B; Weissler M; Yarbrough W; Sheets N; Mendenhall W; Tan XM; Gupta GP
J Clin Oncol; 2020 Apr; 38(10):1050-1058. PubMed ID: 32017652
[TBL] [Abstract][Full Text] [Related]
14. Systematic evaluation and meta-analysis of the prognosis of down-staging human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma using cetuximab combined with radiotherapy instead of cisplatin combined with radiotherapy.
Hu Q; Li F; Yang K
PeerJ; 2024; 12():e17391. PubMed ID: 38784388
[TBL] [Abstract][Full Text] [Related]
15. Triweekly carboplatin as a potential de-intensification agent in concurrent chemoradiation for early-stage HPV-associated oropharyngeal cancer.
Iganej S; Beard BW; Chen J; Buchschacher GL; Abdalla IA; Thompson LDR; Bhattasali O
Oral Oncol; 2019 Oct; 97():18-22. PubMed ID: 31421466
[TBL] [Abstract][Full Text] [Related]
16. Effect of human papillomavirus on patterns of distant metastatic failure in oropharyngeal squamous cell carcinoma treated with chemoradiotherapy.
Trosman SJ; Koyfman SA; Ward MC; Al-Khudari S; Nwizu T; Greskovich JF; Lamarre ED; Scharpf J; Khan MJ; Lorenz RR; Adelstein DJ; Burkey BB
JAMA Otolaryngol Head Neck Surg; 2015 May; 141(5):457-62. PubMed ID: 25742025
[TBL] [Abstract][Full Text] [Related]
17. The impact of Human Papilloma Virus status on the prediction of head and neck cancer chemoradiotherapy outcomes using the pre-treatment apparent diffusion coefficient.
Connor S; Anjari M; Burd C; Guha A; Lei M; Guerrero-Urbano T; Pai I; Bassett P; Goh V
Br J Radiol; 2022 Feb; 95(1130):20210333. PubMed ID: 34111977
[TBL] [Abstract][Full Text] [Related]
18. Gut microbiome predicts gastrointestinal toxicity outcomes from chemoradiation therapy in patients with head and neck squamous cell carcinoma.
Hes C; Desilets A; Tonneau M; El Ouarzadi O; De Figueiredo Sousa M; Bahig H; Filion É; Nguyen-Tan PF; Christopoulos A; Benlaïfaoui M; Derosa L; Alves Costa Silva C; Ponce M; Malo J; Belkad W; Charpentier D; Aubin F; Hamilou Z; Jamal R; Messaoudene M; Soulières D; Routy B
Oral Oncol; 2024 Jan; 148():106623. PubMed ID: 38006691
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of extranodal extension in human papillomavirus-associated oropharyngeal squamous cell carcinoma.
An Y; Park HS; Kelly JR; Stahl JM; Yarbrough WG; Burtness BA; Contessa JN; Decker RH; Koshy M; Husain ZA
Cancer; 2017 Jul; 123(14):2762-2772. PubMed ID: 28323338
[TBL] [Abstract][Full Text] [Related]
20. Survival outcomes with concomitant chemoradiotherapy in older adults with oropharyngeal carcinoma in an era of increasing human papillomavirus (HPV) prevalence.
Lu DJ; Luu M; Nguyen AT; Scher KS; Clair JM; Mita A; Shiao SL; Ho AS; Zumsteg ZS
Oral Oncol; 2019 Dec; 99():104472. PubMed ID: 31704556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
